Congratulation, Ashay Karpe | Best Researcher Award | Award Winner 2023
Dr.Ashay Karpe : Transformational LeadershipProfessional Profile
Early Academic Pursuits:
Dr. Ashay Pramod Karpe embarked on his academic journey at Seth G. S. Medical College, K. E. M. Hospital, Mumbai, where he earned his M.B.B.S. degree from September 1996 to January 2002. His dedication and academic prowess were evident early on, setting the foundation for his future accomplishments.
Moving forward, he pursued M.D. (General Medicine) at Govt. Medical College & Hospital, Aurangabad, from January 2004 to March 2007. Dr. Karpe's exceptional performance during this period was underscored by being awarded the Gold Medal for his achievements.
Professional Endeavors:
Following his postgraduate studies, Dr. Karpe delved into the field of oncology. He attained a D.M. (Medical Oncology) from Tata Memorial Hospital, Mumbai, emerging as a Gold Medallist of the 2012 batch. His training at Tata Memorial Hospital equipped him with expertise in managing Solid Tumours, Haematological Malignancies, and Stem Cell Transplantation.
He further honed his skills through a Fellowship in Clinical Haematology at Tata Medical Center, Kolkata, from May 2011 to July 2012. During this period, he played a pivotal role in establishing a Stem Cell Transplant unit, showcasing his commitment to advancing medical practices.
Contributions and Research Focus:
Dr. Karpe's contributions extend beyond clinical practice. As a Sp. Registrar (Clinical Haematology) at Sahyadri Speciality Hospital, Pune, from June 2007 to November 2010, he conducted numerous Stem Cell Transplants, including Autologous, Allogeneic, Haploidentical, Matched Unrelated Donor, and Cord blood Transplants. His involvement as a Co-principal Investigator in various clinical trials, such as the VANTAGE 088 randomized phase III multi-centric international trial, underscores his commitment to advancing medical research.
His research endeavors are reflected in numerous publications and presentations, covering topics such as the efficacy of second-line Erlotinib in Head and Neck cancers and the frequency of bacterial isolates in patients with hematological malignancies.
Accolades and Recognition:
Dr. Karpe's dedication and excellence have earned him several accolades, including the Outstanding Student Award by HBNI in 2015, the DNB President’s Gold Medal in December 2015, and Gold Medals in DM (Medical Oncology) and MD (General Medicine). These awards are a testament to his outstanding contributions to the field of oncology.
Impact and Influence:
As the Director of Sunrise Oncology Care and President of the Cancer Research & Statistics Foundation, Dr. Karpe holds influential roles in shaping the landscape of oncology care and research. His impact is further amplified through his consultancy at renowned hospitals like P D Hinduja Hospital, Tieten Medcity Hospital, Vedant Hospital, and Cardinal Gracias Memorial Hospital.
Legacy and Future Contributions:
Dr. Ashay Pramod Karpe's legacy is marked by his significant contributions to the field of oncology, spanning clinical practice, research, and leadership roles. His expertise in Solid Tumours, Haematological Malignancies, and Stem Cell Transplantation, coupled with a robust research portfolio, positions him as a key figure in advancing cancer care. As he continues to lead and contribute to the field, Dr. Karpe is poised to leave a lasting legacy of excellence and innovation in oncology.
Notable Publications
- Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
- Drug-sensitiveFGFR3 mutations in lung adenocarcinoma
- Outcomes in treatment-naïve patients with metastatic extremity osteosarcoma treated with OGS-12, a novel non–high-dose methotrexate–based, dose-dense combination chemotherapy …
- Distress management in patients with head and neck cancer before start of palliative chemotherapy: a practical approach
- Expectations and preferences for palliative chemotherapy in head and neck cancers patients
- Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients
- Management of hematological malignancies during the COVID-19 pandemic
- Metronomic palliative chemotherapy in maxillary sinus tumor
- Efficacy of second-line erlotinib in patients postprogression of first-line chemotherapy in head and neck cancers
Citations
A total of 212 citations for his publications, demonstrating the impact and recognition of his research within the academic community.
- Citations 212 192
- h-index 7 7
- i10-index 6 6